A Randomized, Double-Blind Study of Ruxolitinib or Placebo inCombination With Regorafenib in Subjects With Relapsed orRefractory Metastatic Colorectal Cancer - Ruxolitinib in Combination With Regorafenib in Metastatic Colorectal Cancer

Incyte Corporation0 个研究点目标入组 420 人开始时间: 2014年10月3日最近更新: 2017年4月3日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Incyte Corporation
入组人数: 420

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Male or female 18 years or older.
•Histologically or cytologically confirmed adenocarcinoma of the colon or rectum that is metastatic.
•Previous treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF therapy (if no contraindication); and if KRAS wild type and no contraindication, an anti-EGFR therapy; and progressed following the last administration of approved therapy.
•Radiographically measurable or evaluable disease (per RECIST 1.1).
•Eastern Cooperative Oncology Group performance status of 0 to 2.
•Three or more weeks have elapsed from the completion of previous treatment regimen and subjects must have recovered or be at a new stable baseline from any related toxicities.
•Radiotherapy to disease sites is allowed provided:
•- Four or more weeks have elapsed since the completion of radiation therapy.
•- Subjects who received palliative radiation treatment to a limited field or on an accelerated schedule within the last 7 days are eligible
•- Disease sites within the field of prior irradiation have subsequently progressed or there are other metastatic disease sites outside the field of prior irradiation.
•- All treatment related toxicities have resolved or are at a new stable baseline.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 210
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 210

排除标准

•Subjects who meet any of the following will not be included in the study:
•Received prior treatment with regorafenib.
•Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs.
•History of abdominal fistula or gastrointestinal perforation at any point within 6 months prior to day 1 of study drug administration, unless surgically repaired.
•Active peptic ulcer disease, inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), diverticulitis, or other gastrointestinal conditions with increased risk of perforation or gastrointestinal bleeding.
•Recent history (=4 weeks of Day 1 of study drug administration) of a major surgery or significant traumatic injury.
•Recent history (= 3 months) or ongoing partial or complete bowel obstruction unless corrected with surgery.
•Blood pressure = 140/90 mmHg
•Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment.
•Known central nervous system metastases or history of uncontrolled seizures.
•Clinically significant cardiac disease including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, New York Heart Association Class II, III, or IV congestive heart failure, and arrhythmia requiring therapy.
•Creatinine clearance < 50 mL/min measured or calculated by Cockroft-Gault equation
•Inadequate hepatic, and bone marrow function as evidenced by:
•- Absolute neutrophil count < 1.5 × 109/L.
•- Platelets < 100 × 109/L.
•- Hemoglobin < 9 g/dL (transfusions are permitted to achieve baseline hemoglobin level).
•- ALT/AST > 2.5 × the upper limit of normal (ULN); or > 5 × ULN in the presence of liver metastases.
•- Total bilirubin > 1.5 × ULN (if total bilirubin is > 1.5 × ULN then the subject may participate if the direct bilirubin is = 1.5 × ULN).
•Concurrent anticancer therapy
•Subjects who participated in any other study in which an investigational study drug was received within 28 days prior to first dose.
•Current or previous other malignancy within 5 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive malignancy.
•Known HIV infection.
•HBV or HCV viremia or at risk for HBV or HCV reactivation.

研究者

发起方

Incyte Corporation

相似试验

进行中（未招募）

1 期

A Study of Ruxolitinib in Combination With Regorafenib in Subjects Metastatic Colorectal CancerRelapsed or refractory metastatic colorectal cancerMedDRA version: 17.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10010030Term: Colorectal cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2013-004714-18-ATIncyte Corporation427

进行中（未招募）

1 期

EUCTR2013-004714-18-ITIncyte Corporation427

已完成

4 期

ithium carbonate for patients with amyotrophic lateral sclerosis

ISRCTN83178718King's College London (UK)220

已完成

不适用

To study the difference in effect of various drug in patient suffering from Schizophrenia, a kind of mental disorder in which signs and symptoms are variable and include changes in perception, emotion, cognition, thinking, and behaviour.

CTRI/2018/02/011813Department of Pharmacology and therapeutics54

进行中（未招募）

1 期

A Randomized Double-blind study of Ustekinumab in Pediatric Subjects with Crohn's DiseaseModerately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disorders

EUCTR2016-001956-22-PLJanssen-Cilag International N.V.40